CAR T-cell Therapy - Global Market Trajectory & Analytics

Global CAR T-cell Therapy Market to Reach $8.3 Billion by 2027

Amid the COVID-19 crisis, the global market for CAR T-cell Therapy estimated at US$340.7 Million in the year 2020, is projected to reach a revised size of US$8.3 Billion by 2027, growing at a CAGR of 57.7% over the period 2020-2027. CD19, one of the segments analyzed in the report, is projected to record 49.9% CAGR and reach US$4 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the CD22 segment is readjusted to a revised 70.1% CAGR for the next 7-year period.

The U. S. Market is Estimated at $103.7 Million, While China is Forecast to Grow at 55.2% CAGR

The CAR T-cell Therapy market in the U. S. is estimated at US$103.7 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.3 Billion by the year 2027 trailing a CAGR of 55.2% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 50.7% and 49.5% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 39.1% CAGR. We bring years of research experience to this 7th edition of our report. The 112-page report presents concise insights into how the pandemic has impacted production and the buy side for 2020 and 2021. A short-term phased recovery by key geography is also addressed.

Competitors identified in this market include, among others:

• bluebird bio, Inc.
• CARsgen Therapeutics
• Celgene Corporation
• Gilead Sciences, Inc.
• Novartis AG